Myriad Q3 Revenues Dip 2 Percent; FY 2015 Guidance Lowered | GenomeWeb

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday that its third quarter revenues for fiscal year 2015 dipped 2 percent.

For the second quarter in a row, the company also lowered its guidance for the fiscal year.

Total revenues for the three months ended March 31 were $180.0 million compared to $182.9 million in the third quarter of fiscal year 2014. The revenues were below the consensus Wall Street estimate of $183.3 million. Myriad attributed the decrease to severe weather conditions in the northeast during January and February.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.